Triad Healthcare Partners
a division of Triad Securities Corp.
Provides investment banking services to pharmaceutical and medical device companies on a global basis
Andrew Hirchberg and Mark Palmer work with global clients
Providing strategic advisory services related to all aspects of mergers, acquisitions and licensing activities
Andrew Hirschberg
Has been advising clients for 30 years and has completed over 100
transactions in multiple specialties (dermatology, gastroenterology, pediatrics, nephrology, etc.)
with an aggregate value exceeding $5 billion.
Mark Palmer
Led business development for two specialty pharmaceutical companies (Braintree Laboratories, Inc.
and Medicis Pharmaceutical Corp.) for the 10 years prior to joining Triad Healthcare Partners.
During that time, Mark led and completed transactions with an aggregate value of well over $1 billion . These transactions were primarily in
dermatology, gastroenterology, orphan drugs and pediatrics.
vast healthcare-experience in sourcing deals
and representing clients in all aspects of deal making and
negotiation in the global specialty pharmaceutical and medical device sectors
Prior to forming Triad Healthcare Partners , Andrew and Mark worked together as investment bankers at another broker-dealer, where they advised clients on strategic transactions and completed multiple M&A and licensing deals.
Andrew and Mark work with companies throughout the development and commercialization timeline and assist with in/out-licensing and mergers and acquisitions to maximize value for the shareholders of client companies.
Mergers and Acquisitions
Andrew Hirschberg
Head of Investment Banking
Triad Healthcare Partners
Representative Transactions
| CLIENT | TRANSACTION | COUNTERPARTY | DEAL VALUATION |
|---|---|---|---|
| Medicis | Sale of Company | Valeantz | $2.6 B |
| MerzPharma | Company Acquisition | Ulthera | Up to $600M |
| Revision Skincare/ Goodier Cosmetics | Majority Stake Sold | RoundTable Healthcare | Undisclosed |
| Novan, Inc. | Out-license of SB204 (Phase 3, acne) for Japan | Sato Pharmaceutical Co. | Up $42.4M + Royalties |
| Merz Pharma | Sale of Dermatology Assets | Sebela Pharmaceuticals | Undisclosed |
| Neocutis SA | Sale of Company | Merz Pharma | Undisclosed |
| Brickell Biotech | Out-license of hyperhidrosis asset (Phase 2) for Japan/other Asian countries | Kaken Pharmaceutical | Undisclosed |
| Medicis | Acquisition of Company’s Assets | Graceway Pharmaceuticals | $455 M |
| Precision Dermatology | Acquisition of Clindagel Assets | Galderma Laboratories | Undisclosed |
| Braintree Laboratories | Sale of PhosLo Product Line | Nabi Biopharmaceuticals | $120 M |
| Ivax | Acquisition of Nasarel and Nasalide Prod. Lines | Elan Corporation | $140 M |
| Hill Dermaceuticals | Sale of Triluma Product Line | Galderma Laboratories | $100 M+ |
| R&D Laboratories | Sale of Company | Watson Pharmaceuticals | $185 M |
| Braintree Laboratories | Out-license of SuPrep For 50-countries (Ex-North America) | Ipsen Group | Undisclosed |
| Medicis | Sale of Ascent Pediatrics | BioMarin Pharmaceutical | $190 M |
| Ferndale Laboratories | Sale of Locoid Product Line | Triax Pharmaceuticals | $120 M |
| Daniels Pharmaceuticals | Sale of Company | Jones Medical Industries | $130 M |
| Braintree Labratories | Sale of MiraLax OTC Rights | Schering-Plough | Undisclosed |